Researchanalyst

 

Nico Popp

  • Small-Caps

At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories. That it depends thereby less on large names, but on the future potential and whether the market also recognizes these perspectives, was one of its first learnings at the stock exchange.

On these pages, Nico examines current events at listed companies and takes a closer look at companies that are traded under the radar of the market, in addition to well-known securities.

In order to be able to take advantage of speculative opportunities on the stock exchange, Nico not only focuses on a balanced asset allocation of defensive and opportunity-oriented securities, but also on an intact risk management. "In addition to position size and entry in several tranches, investors should also develop a sense of timing and get to know a stock better before investing," says the columnist.


Kommentare von Nico Popp

Kommentar von Nico Popp vom 26.02.2024 | 07:00

Share News: Defence Therapeutics - New study unleashes blockbuster potential

  • ADC
  • cancer research

Pharmaceutical giants have billions to spare. Their preferred acquisition targets focus on antibody-drug conjugates and the fight against cancer - an area in which Defence Therapeutics has been active for years. Previously unpublished studies now reveal entirely new potential for AccuTOX®, a chemotherapy drug on the verge of being approved by the FDA. As the share is extremely interesting from a technical perspective, investors should pay close attention.

Zum Kommentar

Kommentar von Nico Popp vom 26.09.2023 | 06:30

Stock news: Defence Therapeutics - Positive interim results from mRNA comparative study

  • mRNA
  • cancer research

Accum™ enhances mRNA vaccines. To support this claim, Defence Therapeutics conducted a comparative study and reported promising results in late September: In the study, Accum™ doubled the number of antibodies compared to an mRNA vaccine without Accum™. This is a strong indication that the flexible technology, which is expected to move into two Phase I trials as a cancer vaccine and chemotherapeutic in the coming months, may also greatly benefit mRNA vaccines in the future. We look at what matters in the coming weeks and months and why Defence Therapeutics has long been in the sights of potential buyers.

Zum Kommentar

Kommentar von Nico Popp vom 05.07.2023 | 06:00

Stock News: Defence Therapeutics - From the Lab to millions of living rooms in the USA

  • Biotechnology

Short infotainment formats are popular among viewers - for example, before the news or between two movies. The Canadian biotech startup Defence Therapeutics has now been chosen by the series "Viewpoint with Dennis Quaid" as a partner for a series on the opportunities and limitations of biotechnology. For the Company, which is aiming for the Nasdaq, the associated publicity can only be beneficial. What remains decisive, however, is what happens behind the camera. Groundbreaking research is currently underway.

Zum Kommentar

Kommentar von Nico Popp vom 29.06.2023 | 06:15

Stock News: Defence Therapeutics unveils extensive patent portfolio

  • Biotechnology

More is better. According to this motto, the innovative cancer specialist Defence Therapeutics has built an extensive patent portfolio in recent years. Here we discuss the areas in which patents have been filed, what options Defence Therapeutics has as a result, and what will be crucial for the Company, which is facing several clinical trials in 2023 in the coming weeks.

Zum Kommentar

Kommentar von Nico Popp vom 21.06.2023 | 06:00

Defence Therapeutics applies for worldwide patent protection for flexible biotech tool

  • cancer research

Cancer specialist Defence Therapeutics has applied for international patent protection for its versatile Accum™ adjuvant technology. This means that the numerous projects the Company is driving forward in parallel thanks to its platform approach will soon receive a "price tag". Specifically, this involves vaccines against various types of cancer, ranging from skin to pancreatic cancer, some of which will soon be transferred to a Phase I study. The same applies to the promising chemotherapeutic AccuTOX™. We discuss the outlook for the CRISPR "gene scissors," which mRNA study will soon deliver results and the state of takeover activity in the industry.

Zum Kommentar

Kommentar von Nico Popp vom 18.06.2023 | 07:15

Defence Therapeutics targets new types of cancer

  • Biotech
  • mRNA
  • cancer

Curing skin cancer, lymphoma, lung cancer and even pancreatic cancer - the list of promising projects Defence Therapeutics is advancing is long. But despite the wide range of services, Defence Therapeutics' projects go hand in hand. The reason lies in the Accum™ technology, whose platform approach is now protected by the US Patent Office. Below you can find out about the current status of Defence Therapeutics' projects, where the journey may take us in the coming weeks, and in which area Defence Therapeutics could spring a surprise.

Zum Kommentar

Kommentar von Nico Popp vom 25.04.2023 | 06:00

BioNxt wins customers - Landmark ruling in the US clears the way for rotigotine patches

  • Biotech
  • Parkinson

The Canadian-German biotech company BioNxt has won an international pharmaceutical company as a customer and concluded a development and manufacturing contract. An orally soluble product based on BioNxt's platform will be developed and manufactured at the site of its German subsidiary Vektor Pharma TF GmbH in Baden-Württemberg, Germany. According to a company release, the contract has been signed and partially paid. About a week ago, BioNxt reported the purchase of a coating and cutting machine to expand commercial manufacturing capacity. Now, things could also move very quickly with another product from BioNxt.

Zum Kommentar

Kommentar von Nico Popp vom 20.04.2023 | 06:00

Pipelines from BioNTech, Moderna and Defence Therapeutics: "It's a match!"

  • mRNA
  • cancer
  • biotechnology

Curing cancer is a dream of humanity. However, when looking at mRNA projects from large companies such as BioNTech or Moderna, a higher survival rate is still considered a success. Moderna, together with the US pharmaceutical company Merck, Sharpe & Dohme (MSD), has now shown that an mRNA vaccine can reduce the mortality of seriously ill skin cancer patients by 40%. This article looks at how Moderna's project relates to Defence Therapeutics, where it connects to BioNTech's projects, and why adjuvant technology is critical in mRNA vaccines.

Zum Kommentar

Kommentar von Nico Popp vom 18.04.2023 | 07:30

BioNxt creates production capacities in Germany

  • biotechnology

Things are happening at the Canadian-German biotech company BioNxt Solutions. Just at the beginning of March, the Company acquired a technology for the enteric coating of tablets. Now things are moving in leaps and bounds. Over the weekend, BioNxt reported that a company contractor has completed initial prototypes of tablets coated with the new technology. The tablets contain active pharmaceutical ingredients and may be used in bioavailability pilot studies. BioNxt is currently exploring opportunities to evaluate its new coating technology in studies.

Zum Kommentar

Kommentar von Nico Popp vom 18.04.2023 | 06:00

Defence Therapeutics has started mRNA studies - results in 6 weeks

  • mRNA
  • Accum
  • cancer research

Canadian biotech company Defence Therapeutics has taken the next step on its journey to improve mRNA vaccines using its Accum™ technology. To this end, the Company has begun comparative studies pitting a "naked" mRNA vaccine against the combination of mRNA vaccine and Accum™. In this article, we discuss how the Canadians are proceeding, why CEO Sébastien Plouffe is confident, and which USD 43 billion acquisition may also give hope to shareholders of Defence Therapeutics.

Zum Kommentar